
Good Sunday, all. An exciting set of papers in #cancermetabolism and #mitochondrialbiology is here, hot off the press. Find it here: biomed.news/bims-camemi/2026… @Bims_BiomedNews @mitoworld_org #keepreading #keepthinking

Alex Puissant, Ph.D., is a Principal Investigator in the Hematology-Oncology Department at the Saint Louis Research Institute & Hospital, Paris, France.

Good Sunday, all. An exciting set of papers in #cancermetabolism and #mitochondrialbiology is here, hot off the press. Find it here: biomed.news/bims-camemi/2026… @Bims_BiomedNews @mitoworld_org #keepreading #keepthinking

Now out in Nature Cell Biology. Five labs brought quantitative proteomics, ribosome profiling, single-molecule imaging, preclinical models and patient-cohort analyses to bear on the unforeseen reach of the K55 dimethylation mark on elongation factor 1A. nature.com/articles/s41556-0…

1/. New publication alert! 🚨 Our lab’s multi-year collaborative work with the labs of @gsducker and @RutterLab just published in @Nature. Our work led to the discovery of a new pathway through which the heart can use lactate to generate energy. nature.com/articles/s41586-0…

Thank you for supporting me from the beginning.
A civil jury vindicates David Sabatini, awarding him $6M in damages.

“The oncogenic control of nucleotide synthesis” 🔵 Excited to share the latest review from Issam Ben-Sahra (@bensahralab), now available in #Oncogenesis. ▶️ Read the full review here: nature.com/articles/s41389-0…

ANNOUNCING THE 2026 WOLF PRIZE LAUREATES IN CHEMISTRY The 2026 Wolf Prize in Chemistry is awarded to Pascal Mayer, Shankar Balasubramanian and David Klenerman for developing impactful, low-cost, next generation DNA sequencing methods for genomic medicine. Their work helped transform DNA sequencing into a technology capable of operating at extraordinary speed and scale. Balasubramanian and Klenerman pioneered a massively parallel sequencing approach that contributed to a million-fold improvement in sequencing speed and cost, helping make it possible to sequence a human genome for under $200. Mayer played a pivotal role in turning those breakthroughs into a practical high-throughput sequencing system, integrating the chemistry, microfluidics, optics and computational components needed to make the technology work at scale. Today, the sequencing platform that grew from this work forms the technological foundation for more than 90% of global sequencing data, powering major advances in genomics and precision medicine. Congratulations to the 2026 Wolf Prize Laureates in Chemistry! @Cambridge_Uni @universitedestrasbourg

An invasion of immune cells from skull bone marrow triggers inflammation that drives cognitive and mood decline with age in adults with chronic #TBI, shows work that also identifies #fenofibrate as a promising therapy in a pilot trial. scim.ag/3Tthp9c

Happy to see our paper, led by outstanding postdoc Alessandra Esposito, out in @Nature today. We uncovered a TBK1/ULK1 signaling pathway that acts as a lysosome quality control mechanism, regulating the FLCN-TFEB axis in response to lysosomal stress Link: rdcu.be/icEViqq6F68a

How does metabolism shape anti-tumor immunity and can we use it to make immunotherapy work better? A great new review in @Oncogenesis_ on this rapidly moving field. Many thanks to @LabPuissant @camille_lobry @BenajibaLina , N Fenouille nature.com/articles/s41389-0…

Splicing Dysregulation as a Key Driver of Chemoresistance and Relapse in AML - @LabPuissant @camille_lobry oncodaily.com/voices/alex-pu…

Weekly selection of papers in myeloid leukemia biology and therapy is out! Enjoy it and thanks as always @Bims_BiomedNews biomed.news/bims-tremyl/2026…

Profiling a relapse AML cohort and leveraging in vivo functional genomics, we uncovered an actionable SRRM1–CLK1/4–PAK1 node driving chemoresistance and MAP2K5 missplicing as a key relapse-associated event. Dual PAK1/CLK1/4 inhibition restores chemosensitivity.

Excited to share our latest study with @camille_lobry! Using multiple AML models, we identified splicing dysregulation as a key feature of chemoresistance and relapse in AML. @Institut_IRSL @Leukemia_Inst @ScienceTM tinyurl.com/mt932jky
Thrilled to share the publication of our latest piece of research in @ScienceTM, in collaboration with and led by the amazing @LabPuissantand Camille Vaganay Why does acute myeloid leukemia (AML) so often relapse after chemo works at first? tinyurl.com/mt932jky 🧵

A new study demonstrates how kidney-infiltrating T cells may contribute to kidney injury in patients with lupus, phage therapy switches off malicious E. coli to calm colitis in Crohn's disease in mice, and more this week in #ScienceTranslationalMedicine. scim.ag/4wz8nFC

We're #hiring! I'm excited to announce that my lab @StJudeResearch is hiring a post-doctoral research associate. Come join our fabulous team of researchers! #osteosarcoma #childhoodcancer talent.stjude.org/careers/Jo…

A #MachineLearning model based on 11 plasma protein markers predicts the risk of #thrombosis in patients with #cancer more accurately than standard risk scores, and uncovers IL-17A as a potential therapeutic target. @jzbos @ioavlachos @BIDMChealth scim.ag/4vkCkZO